Wednesday, July 11, 2007

Genentech profit up on Avastin, Rituxan

(Reuters) - Genentech had a profit of 78 cents per share for the quarter excluding stock-based compensation expenses and other items and posted total operating revenue of $3.0 billion, up from $2.2 billion a year ago. Both beat Wall Street forecasts.




Analysts, on average, had expected the South San Francisco-based company to post second-quarter earnings before items of 71 cents per share on revenue of $2.85 billion, according to Reuters Estimates.


Read more at Reuters.com Hot Stocks News

No comments: